Recombinant human PD-L1 protein (Active)
- Bioactive
- What is this?
Be the first to review this product! Submit a review
|
(6 Publications)
Recombinant human PD-L1 protein (Active) is a Human Fragment protein, in the 19 to 238 aa range, expressed in HEK 293 cells, with >98%, < 1 EU/µg endotoxin level, suitable for SDS-PAGE, HPLC, FuncS.
View Alternative Names
CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1, Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, hPD-L1, B7 homolog 1, B7-H1
- FuncS
Supplier Data
Functional Studies - Recombinant human PD-L1 protein (Active) (AB167713)
Anti-Human PD-L1 Mab (Human IgG1), captured on CM5 chip via anti-human IgG Fc antibodies surface, binds ab167713 with an affinity constant of 0.286 nM, as determined in a SPR assay (Biacore T200) (Routinely tested).
- FuncS
Supplier Data
Functional Studies - Recombinant human PD-L1 protein (Active) (AB167713)
Human PD-1, Fc Tag (ab221398), captured on CM5 chip via anti-human IgG Fc antibody, binds ab167713 with an affinity constant of 3.6 μM, as determined in an SPR assay (Biacore T200).
- FuncS
Unknown
Functional Studies - Recombinant human PD-L1 protein (Active) (AB167713)
The purity of Human PD-L1 (His Tag) (HPLC verified) was greater than 90% as determined by SEC-HPLC.
- FuncS
Supplier Data
Functional Studies - Recombinant human PD-L1 protein (Active) (AB167713)
Loaded Recombinant human PD1 protein (Fc Chimera Active) ab221398 on ProteinA Biosensor, can bind Human PD-L1, His Tag ab167713 with an affinity constant of 5.3 μM as determined in BLI assay.
- FuncS
Supplier Data
Functional Studies - Recombinant human PD-L1 protein (Active) (AB167713)
Immobilized ab167713 at 1 μg/mL (100 μL/well) binds Anti-Human PD-L1 MAb (Human IgG1).
Linear range of 0.1-3 ng/mL (QC tested).
- FuncS
Supplier Data
Functional Studies - Recombinant human PD-L1 protein (Active) (AB167713)
Immobilized ab167713 on Anti-His Tag (C-term) Antibody, precoated (0.1 μg/well) plate, binds Human PD-1, Mouse IgG2a Fc Tag (HPLC-verified), at 5 μg/mL (100 μL/well).
Linear range of 10-78 ng/mL (Routinely tested).
- FuncS
Supplier Data
Functional Studies - Recombinant human PD-L1 protein (Active) (AB167713)
Biotinylated Human PD-1, Fc Tag (ab246137) binds Recombinant human PD-L1 protein ab167713 at 1 μg/mL (5μL/well).
Linear range of 0.02-0.625 μg/mL as determined in a alphaLISA homogeneous assay (Routinely tested).
- SDS-PAGE
Supplier Data
SDS-PAGE - Recombinant human PD-L1 protein (Active) (AB167713)
Reduced ab167713 on SDS-PAGE, stained overnight with Coomassie Blue.
The purity of the protein is greater than 98%.
The protein migrates as 30-35 kDa under reducing conditions, due to glycosylation.
Reactivity data
Sequence info
Properties and storage information
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
PD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.
Pathways
PD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.
Specifications
Form
Lyophilized
Additional notes
>90% as determined by SEC-HPLC.Purified by Immobilized metal affinity chromatography.
General info
Function
Plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 11015443, PubMed : 28813410, PubMed : 28813417, PubMed : 31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed : 11015443, PubMed : 28813410, PubMed : 28813417, PubMed : 36727298). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed : 10581077). Can also act as a transcription coactivator : in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed : 32929201).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 28813410, PubMed : 28813417). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).
Sequence similarities
Belongs to the immunoglobulin superfamily. BTN/MOG family.
Post-translational modifications
Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation (PubMed:28813410). Ubiquitinated by MARCHF8; leading to degradation (PubMed:34183449). Deubiquitinated by USP22; leading to stabilization (PubMed:31399419).
Target data
Publications (6)
Recent publications for all applications. Explore the full list and refine your search
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 11:e2309917 PubMed38520717
2024
Applications
Unspecified application
Species
Unspecified reactive species
Journal of immunology (Baltimore, Md. : 1950) 212:917-927 PubMed38214607
2024
Applications
Unspecified application
Species
Unspecified reactive species
Molecular therapy : the journal of the American Society of Gene Therapy 31:2929-2947 PubMed37515321
2023
Applications
Unspecified application
Species
Unspecified reactive species
International journal of molecular sciences 24: PubMed36982608
2023
Applications
Unspecified application
Species
Unspecified reactive species
International journal of molecular sciences 22: PubMed34948105
2021
Applications
Unspecified application
Species
Unspecified reactive species
ChemMedChem 16:568-577 PubMed33085193
2020
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com